当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.

Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.

Abstract：

:This phase II study of liarozole fumarate (R85246, liarozole), a novel imidazole with retinomimetic and aromatase inhibitory effects, was designed to determine the efficacy and tolerability in postmenopausal women with advanced breast cancer in progression, to correlate these effects with hormonal levels, and to evaluate quality of life. Twenty-nine women with ER-positive or unknown metastatic disease who received > or = 2 prior hormonal therapies were treated with 150-300 mg liarozole twice daily until disease progression. All patients were evaluable for toxicity and 25 for response. Four patients (16.0%, 95% CI 5.3-37.4%) had partial remission (PR) of their disease for a median of 7.4 months (range 1.2-12.9) and 7 (28%) had disease stabilization for a median of 4.8 months (1.6-16.0). Estradiol decreased from pre-treatment levels of 9.2-52 pM (mean 17.1) to below detection (9.2 pM, p = 0.0005) after 1 month. Similarly estrone levels fell from 14-307 pM (mean 92.7) to below detection (9.2 pM, p = 0.0001). The most common toxicity was dermatological (96.6%) with features compatible with hypervitaminosis A syndrome such as rash, pruritus, dry skin, and brittle nails. The majority of these were mild to moderate in severity. No significant improvement in quality of life scores (FLI-C) were noted. Liarozole is an active new treatment for breast cancer in patients heavily pre-treated with hormone therapies. Further studies are needed to confirm its relative efficacy in both receptor positive and negative postmenopausal breast cancer.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Goss PE,Oza A,Goel R,Nabholtz JM,De Coster R,Bruynseels J,Reid C,Wadden N,Crump M,Tye LM

doi

10.1023/a:1006320122711

subject

Has Abstract

pub_date

2000-01-01 00:00:00

pages

55-68

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

59

pub_type

临床试验,杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy.

    abstract：:Metastasizing cancer cells can invade the extracellular matrix using plasma membrane protrusions, termed invadopodia, that contact and dissolve the matrix. Various membrane associated proteases localized on the invadopodial membranes are responsible for the extracellular matrix degradation. Work from our laboratory sh...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666155

    authors： Chen WT,Lee CC,Goldstein L,Bernier S,Liu CH,Lin CY,Yeh Y,Monsky WL,Kelly T,Dai M

    更新日期：1994-01-01 00:00:00

  • Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

    abstract：PURPOSE:In our microarray analysis we observed that Seven-in-Absentia Homolog 2 (SIAH2) levels were low in estrogen receptor (ER) positive breast tumors of patients resistant to first-line tamoxifen therapy. The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0125-z

    authors： Jansen MP,Ruigrok-Ritstier K,Dorssers LC,van Staveren IL,Look MP,Meijer-van Gelder ME,Sieuwerts AM,Helleman J,Sleijfer S,Klijn JG,Foekens JA,Berns EM

    更新日期：2009-07-01 00:00:00

  • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.

    abstract：PURPOSE:Platinum plays an important role in the treatment of triple-negative breast cancer (TNBC) in neoadjuvant and metastatic settings. However, its role in an adjuvant setting remains unclear. METHODS:In this non-inferior randomized phase 2 trial, we randomly assigned 308 chemotherapy-naive patients with histologic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-020-05648-9

    authors： Du F,Wang W,Wang Y,Li M,Zhu A,Wang J,Cai R,Ma F,Fan Y,Li Q,Zhang P,Todorovic V,Yuan P,Xu B

    更新日期：2020-07-01 00:00:00

  • Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.

    abstract：PURPOSE:We investigated the oncologic outcomes by intrinsic subtype and age in young breast cancer patients and whether survival differences were related to treatment changes over time. METHODS:A retrospective analysis was performed on 9633 invasive breast cancer patients treated at Asan Medical Center from January 19...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4331-4

    authors： Yoon TI,Hwang UK,Kim ET,Lee S,Sohn G,Ko BS,Lee JW,Son BH,Kim S,Ahn SH,Kim HJ

    更新日期：2017-09-01 00:00:00

  • Immunohistochemical and molecular subtypes of breast cancer in Nigeria.

    abstract：OBJECTIVE:Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations. METHO...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9694-5

    authors： Adebamowo CA,Famooto A,Ogundiran TO,Aniagwu T,Nkwodimmah C,Akang EE

    更新日期：2008-07-01 00:00:00

  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

    abstract：:To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1776-8

    authors： Lortholary A,Hardy-Bessard AC,Bachelot T,de Rauglaudre G,Alexandre J,Bourgeois H,Jaubert D,Paraiso D,Largillier R

    更新日期：2012-01-01 00:00:00

  • Availability of prior mammograms affects incomplete report rates in mobile screening mammography.

    abstract：PURPOSE:Mobile mammography can improve access to screening mammography in rural areas and underserved populations. We evaluated the frequency of incomplete reports in mobile mammography screening and the relationships between prior mammograms and recall rates. METHODS:The frequency of incomplete mammogram reports, the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4861-4

    authors： Roubidoux MA,Shih-Pei Wu P,Nolte ELR,Begay JA,Joe AI

    更新日期：2018-10-01 00:00:00

  • Breast cancer expresses functional NMDA receptors.

    abstract：:We demonstrate here that functional NMDAR1 and NMDAR2 receptors are expressed by Mcf-7 and SKBR3 breast cancer cell lines, and possibly by most or all high-grade breast tumors, and that these receptors are important for the growth of human breast cancer xenografts in mice. RT-PCR demonstrated mRNA for both NMDAR1 and ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0556-1

    authors： North WG,Gao G,Memoli VA,Pang RH,Lynch L

    更新日期：2010-07-01 00:00:00

  • Taste and smell perception and quality of life during and after systemic therapy for breast cancer.

    abstract：PURPOSE:The purpose of the study was to assess self-reported taste and smell perception after chemotherapy in breast cancer patients compared with women without cancer, and to assess whether taste and smell perception is associated with quality of life after the end of chemotherapy. METHODS:We included 135 newly diagn...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4720-3

    authors： de Vries YC,Boesveldt S,Kelfkens CS,Posthuma EE,van den Berg MMGA,de Kruif JTCM,Haringhuizen A,Sommeijer DW,Buist N,Grosfeld S,de Graaf C,van Laarhoven HWM,Kampman E,Winkels RM

    更新日期：2018-07-01 00:00:00

  • Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02).

    abstract：PURPOSE:To evaluate the loco-regional recurrence (LRR) rate after breast-conserving surgery without postoperative radiotherapy (RT) for ductal carcinoma in situ (DCIS) of the breast. METHODS:Between 2000 and 2010, 311 DCIS patients from 9 institutions were analyzed retrospectively. The median age was 47 (range, 20-82)...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-017-4111-1

    authors： Kim K,Jung SY,Shin KH,Kim JH,Han W,Lee HB,Huh SJ,Choi DH,Park W,Ahn SD,Kim SS,Kim JH,Suh CO,Kim YB,Kim IA,Kim S,Kim YJ

    更新日期：2017-02-01 00:00:00

  • High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

    abstract：:Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the biomarkers from serum of patients receiving lapatinib and capecitabine Patients received lapatinib 1,250 mg once daily and capecitabine 2,000 ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-010-1200-9

    authors： Rhee J,Han SW,Cha Y,Ham HS,Kim HP,Oh DY,Im SA,Park JW,Ro J,Lee KS,Park IH,Im YH,Bang YJ,Kim TY

    更新日期：2011-01-01 00:00:00

  • NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

    abstract：:Resistance to endocrine therapy is a major clinical challenge in current treatment of estrogen receptor-positive breast cancer. The molecular mechanisms underlying resistance are yet not fully clarified. In this study, we investigated whether NFκB signaling is causally involved in antiestrogen resistant cell growth an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2053-1

    authors： Yde CW,Emdal KB,Guerra B,Lykkesfeldt AE

    更新日期：2012-08-01 00:00:00

  • Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis.

    abstract：BACKGROUND:The aims of this study were to define the distribution of caveolin 2 (CAV2) in frozen and formalin fixed, paraffin embedded (FFPE) normal breast samples and the significance of CAV2 expression in breast cancer. METHODS:Caveolin 2 distribution in frozen and paraffin-embedded whole tissue sections of normal b...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9718-1

    authors： Savage K,Leung S,Todd SK,Brown LA,Jones RL,Robertson D,James M,Parry S,Rodrigues Pinilla SM,Huntsman D,Reis-Filho JS

    更新日期：2008-07-01 00:00:00

  • miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.

    abstract：PURPOSE:Ductal carcinoma in situ (DCIS) is well-known precursor of invasive ductal carcinoma (IDC). Parts of patients show recurrence as DCIS or IDC after local treatment, but there are no established markers predicting relapse. We analyzed changes in miRNA and oncogene expression during DCIS progression/evolution to i...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05192-1

    authors： Lee J,Kim HE,Song YS,Cho EY,Lee A

    更新日期：2019-07-01 00:00:00

  • Effects of autotransplanted lymph node fragments on the lymphatic system in the pig model.

    abstract：:Secondary lymphedema often develops after removal of lymph nodes in combination with radiation therapy, in particular in patients with breast cancer, inguinal cancer, cervical cancer and melanoma. No convincing treatment for the prevention and therapy of acquired lymphedema exists so far, therefore we wanted to show t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0367-4

    authors： Blum KS,Hadamitzky C,Gratz KF,Pabst R

    更新日期：2010-02-01 00:00:00

  • Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.

    abstract：:The regulation of gene expression by steroid hormones plays an important role in the normal development and function of many organs, as well in the pathogenesis of endocrine-related cancers. Previous experiments have shown that many kallikrein genes are under steroid hormone regulation in breast cancer cell lines. We ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9312-y

    authors： Paliouras M,Diamandis EP

    更新日期：2007-03-01 00:00:00

  • Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.

    abstract：:Although a significant proportion of familial aggregation of breast cancer remains unexplained, many of the currently known breast cancer susceptibility genes, including BRCA1, BRCA2 and TP53, play a role in maintaining genome integrity by engaging in DNA repair. RAD51L1 is one of the five RAD51 paralogs involved in h...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1539-6

    authors： Johnson J,Healey S,Khanna KK,kConFab.,Chenevix-Trench G

    更新日期：2011-08-01 00:00:00

  • Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study.

    abstract：:The objective of this nationwide prospective cohort study is to find out the risk of breast cancer (BC) in relatives of patients with multiple BCs by laterality and age at diagnosis of first BC. Having family history of single (HR 1.8; 95 % CI 1.8-1.9) or multiple (HR 2.7; 95 % CI 2.6-2.9) BC was associated with highe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2848-3

    authors： Kharazmi E,Chen T,Narod S,Sundquist K,Hemminki K

    更新日期：2014-02-01 00:00:00

  • Body fat distribution in relation to breast cancer in women participating in the DOM-project.

    abstract：:The association between body fat distribution and breast cancer risk was studied in 5923 pre- and 3568 post-menopausal women, participating in a breast cancer screening project (the DOM-project in Utrecht, the Netherlands). Cases were fifty six premenopausal women and thirty eight postmenopausal women with breast canc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666491

    authors： den Tonkelaar I,Seidell JC,Collette HJ

    更新日期：1995-04-01 00:00:00

  • Analyzing factors associated with women's attitudes and behaviors toward screening mammography using design-based logistic regression.

    abstract：:We examined the factors associated with screening mammography adherence behaviors and influencing factors on women's attitudes toward mammography in non-adherent women. Design-based logistic regression models were developed to characterize the influencing factors, including socio-demographic, health related, behaviora...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2850-9

    authors： Madadi M,Zhang S,Yeary KH,Henderson LM

    更新日期：2014-02-01 00:00:00

  • Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).

    abstract：PURPOSE:Estimated glomerular filtration rate (eGFR) is commonly used to calculate carboplatin doses and capping the eGFR may be used to reduce the risk of excessive dosing and toxicity. We sought to retrospectively examine the impact of our carboplatin guidelines on pathological complete response rates (pCR) and toxici...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05868-z

    authors： Howell SJ,Coe F,Wang X,Horsley L,Ekholm M

    更新日期：2020-11-01 00:00:00

  • Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.

    abstract：:Locally advanced breast cancer (LABC) is a good setting in which to monitor response to neoadjuvant chemotherapy, to downsize the tumor (which facilitates breast-conserving surgery), and to test newer agents in untreated patients. Eribulin (E) has shown activity in patients who have undergone previous taxane, anthracy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-015-3466-4

    authors： Abraham J,Robidoux A,Tan AR,Limentani S,Sturtz K,Shalaby I,Alcorn H,Buyse ME,Wolmark N,Jacobs SA

    更新日期：2015-07-01 00:00:00

  • Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.

    abstract：INTRODUCTION:Oncoplastic breast surgery (OBS) has developed as an extension of breast-conserving surgery (BCS) in an effort to improve esthetic and functional outcome following surgery for breast cancer. The aim of the present study was to evaluate the possible benefits of OBS, as compared with BCS, with regard to heal...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05544-2

    authors： Rose M,Svensson H,Handler J,Hoyer U,Ringberg A,Manjer J

    更新日期：2020-02-01 00:00:00

  • Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.

    abstract：PURPOSE:To investigate whether fertility preservation (FP) in adult women diagnosed with breast cancer (BC) may impact the time interval between diagnosis and start of chemotherapy in an adjuvant or neo-adjuvant setting. METHODS:Retrospective cohort study of breast cancer patients diagnosed between January 2012 and De...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05858-1

    authors： D'Hondt C,Vanhoeij M,Van Moer E,Segers I,Fontaine C,Tournaye H,De Vos M

    更新日期：2020-11-01 00:00:00

  • Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients.

    abstract：BACKGROUND:The aim was to prove the low identification rate of sentinel lymph node biopsy (SNB) and to determine the feasibility of replacing axillary lymph node dissection (AND) in axillary lymph node positive patients after chemotherapy. METHODS:From October 2001 to July 2005, 875 consecutive patients with primary o...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-006-9330-9

    authors： Lee S,Kim EY,Kang SH,Kim SW,Kim SK,Kang KW,Kwon Y,Shin KH,Kang HS,Ro J,Lee ES

    更新日期：2007-05-01 00:00:00

  • Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.

    abstract：:We evaluated the question of whether the chemosensitizers verapamil and quinine given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed verapamil sensitization of Adriamycin resistance in 18.8% of fresh human bre...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1005716214718

    authors： Taylor CW,Dalton WS,Mosley K,Dorr RT,Salmon SE

    更新日期：1997-01-01 00:00:00

  • Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast.

    abstract：:Following mastectomy, patients with operable breast cancer underwent postoperative irradiation of the chest wall and regional lymph nodes. They were then assigned at random to receive no further therapy, ovarian irradiation (2000 rad in five days) or ovarian irradiation in the same dosage plus prednisone, 7.5 mg daily...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01855127

    authors： Meakin JW,Allt WE,Beale FA,Bush RS,Clark RM,Fitzpatrick PJ,Hawkins NV,Jenkin RD,Pringle JF,Reid JG

    更新日期：1983-01-01 00:00:00

  • Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR.

    abstract：:The research question of this investigation is whether the reduction rate of Ki-67 after neoadjuvant chemotherapy (NAC) could indicate a survival in patients with non-pCR. A total of 455 patients had received NAC, and subsequent surgery was analyzed retrospectively. Patients with non-pCR were divided into three subgro...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3084-6

    authors： Matsubara N,Mukai H,Masumoto M,Sasaki M,Naito Y,Fujii S,Wada N

    更新日期：2014-08-01 00:00:00

  • The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines.

    abstract：:Meta-analyses of microarray data indicate that GATA3 is co-expressed with estrogen receptor alpha (ER) in breast cancer cells. While the significance of this remains unclear, it is thought that GATA3 may serve as a prognostic indicator in breast tumors and may play a role in ER signaling. Recently, reciprocal regulati...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0517-8

    authors： Licata LA,Hostetter CL,Crismale J,Sheth A,Keen JC

    更新日期：2010-07-01 00:00:00

  • The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.

    abstract：:Platinum agents such as cisplatin and carboplatin are DNA-damaging agents with activity in breast cancer (BC), particularly in the triple negative (TN) subgroup. The utility of platinum agents, in addition to standard neoadjuvant chemotherapy (NAC), is controversial. To assess the activity of platinum agents in patien...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-014-2876-z

    authors： Petrelli F,Coinu A,Borgonovo K,Cabiddu M,Ghilardi M,Lonati V,Barni S

    更新日期：2014-04-01 00:00:00